New handheld device could spot concussions in minutes

NCT ID NCT05588115

Recruiting now Diagnosis Sponsor: University of Calgary Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether a small, handheld biosensor can accurately measure a brain injury protein (GFAP) in the blood of people with mild concussions. Researchers will compare the sensor's results to standard lab tests and track symptoms over 12 weeks. If it works, this device could allow for rapid, low-cost concussion diagnosis in emergency rooms or even at home.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: handheld biosensor for GFAP measurement
What this could lead to: If successful, this could lead to a simple, rapid test for concussion that patients can use at home, reducing the need for hospital visits.
What could go wrong: This is an early observational study, so the biosensor may not match lab accuracy. It also only includes mild concussions, so results may not apply to severe cases.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONCUSSION, MILD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Brain Concussion

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CONCUSSION, MILD

Contacts and locations

Locations

Foothills Medical Centre
RECRUITING

Calgary, Alberta, T2N 2T9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.